| Wall Street Journal. Europe 1999 Stephen D. Moore |
| Title | Subject | Authors |
|---|
| Alliance propels PowderJect stock.(Abstract) | Business, international | Stephen D. Moore |
| AstraZeneca arrives ahead of schedule; merged drugs company will be world no. 3. | Business, international | Stephen D. Moore |
| AstraZeneca gets close to end of auction of unit.(AstraZeneca specialty chemicals unit gets bids from Kohlberg Kravis Roberts and Co., Cinven Group Ltd. and Investcorp) | Business, international | Stephen D. Moore, Paul M. Sherer |
| AstraZeneca may consider selling unit.(Abstract) | Business, international | Stephen D. Moore |
| AstraZeneca may remain volatile stock.(Brief Article)(Statistical Data Included) | Business, international | Stephen D. Moore |
| BASF pretax profit fell 50% in quarter.(Abstract) | Business, international | Stephen D. Moore |
| Bayer anticipates stagnant sales in 1999.(Abstract) | Business, international | Stephen D. Moore |
| Bayer is changing its prescription for a turnaround.(possible alliance in life sciences business)(Company Profile) | Business, international | Stephen D. Moore |
| Bayer posts healthy rise in second-quarter profit.(Abstract) | Business, international | Stephen D. Moore |
| British Biotech shares fall by 16% after drug trial. | Business, international | Stephen D. Moore |
| British Biotech to look for deals in European biotechnology sector.(Abstract) | Business, international | Stephen D. Moore |
| Celltech to acquire Chiroscience.(Cambridge, England-based Chiroscience Group PLC acquired by Slough, England-based Celltech PLC) | Business, international | Stephen D. Moore |
| Charges pull BASF's pretax profit down. | Business, international | Stephen D. Moore |
| Dr. Dexter plays sheriff in DNA gold rush: Wellcome Trust turns fight for gene rights into sharing experience.(Statistical Data Included) | Business, international | Stephen D. Moore |
| Genetic research spawns Qiagen revolution.(Qiagen N.V.) | Business, international | Stephen D. Moore |
| Glaxo is set back on antidiabetes drug.(Abstract) | Business, international | Stephen D. Moore |
| Glaxo unveils manufacturing overhaul.(Abstract) | Business, international | Stephen D. Moore |
| Hoechst still unsure of merger backing; but strides made toward Rhone-Poulenc union.(Hoechst AG, Rhone-Poulenc SA, Kuwait Petroleum Corp.)(Abstract) | Business, international | Stephen D. Moore |
| Hoechst to sell significant Clariant stake. | Business, international | Stephen D. Moore, Margaret Studer |
| Hoecsht outlines forecast for growth of divisions.(Abstract) | Business, international | Stephen D. Moore |
| Medarex goes to Europe for alliance on new unit. | Business, international | Stephen D. Moore |
| Medeva's top drug slips, spurring 46% profit plunge.(Abstract) | Business, international | Stephen D. Moore |
| Merck sells stake in marketing deal for 870 million euros. | Business, international | Stephen D. Moore |
| Novartis names CEO Vasella to be next chairman. (Daniel Vasella succeeds Alex Krauer). | Business, international | Stephen D. Moore |
| Novartis reaches a crossroads as drug sales dwindle. | Business, international | Stephen D. Moore |
| Novartis takes scythe to Agrochem division; plan to slash 1,100 jobs seen reaping bumper.(Novartis AG of Switzerland) | Business, international | Stephen D. Moore |
| Novo Nordisk plans radical corporate strategy.(Abstract) | Business, international | Stephen D. Moore |
| Pair show how to beat U.S. bidders; acting jointly, Investcorp, Cinven win.(bidding for the specialty-chemicals division of AstraZeneca PLC) | Business, international | Stephen D. Moore |
| Rhone-Poulenc operating earnings leap.(Abstract) | Business, international | Stephen D. Moore |
| Roche, Decode Genetics locate bone disease gene. | Business, international | Stephen D. Moore |
| Roche earnings increased 15% during first half.(Abstract) | Business, international | Stephen D. Moore |
| Roche plans to spin off fragrance division in 2000.(Abstract) | Business, international | Stephen D. Moore |
| Roche's 2nd-quarter sales jumped 10% on demand for Xenical, other drugs.(Abstract) | Business, international | Stephen D. Moore |
| Roche's antiobesity drug clears hurdle; U.S. panel's marketing clearance boosts stock.(Roche Holding Ltd's Xenical) | Business, international | Stephen D. Moore |
| Roche's chairman plans to retire in early 2001.(Abstract) | Business, international | Stephen D. Moore |
| Sanofi-Synthelabo's net rises by 21%.(But outlook dims as Elf decides to trim stake.) | Business, international | Stephen D. Moore, David Woodruff |
| Schering targets biotech firms; drug maker looks to revive sales.(includes related article about Claritin)(Statistical Data Included) | Business, international | Stephen D. Moore, Shailagh Murray |
| SmithKline abandons expansion efforts by selling 2 units, shuffling executives.(Abstract) | Business, international | Stephen D. Moore, Elyse Tanouye |
| SmithKline Beecham is in talks to sell its DPS Pharmacy unit for possible loss.(Abstract) | Business, international | Stephen D. Moore, Elyse Tanouye |
| UBS in pact to buy GAM for growth. | Business, international | Stephen D. Moore |
| Viag, Algroup deal dies in dispute over valuation.(Abstract) | Business, international | William Boston, Stephen D. Moore |
| Zeneca shareholders to decide Astra deal; few bars remain to creating No. 3 drug firm. | Business, international | Stephen D. Moore |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
